(183) Formulation of Mesoscale Lipid Nanoparticles for Targeted Nucleic Acid Delivery to the Kidneys

Introduction: Healthcare faces significant challenges with the rising prevalence of kidney diseases (1) and current treatments are limited (2). Previous research showed that mesoscale nanoparticles (MNPs) (300 – 400 nm) selectively deliver drugs to the kidneys (3,4), potentially improving their therapeutic efficacy. Lipid nanoparticles have successfully delivered fragile biological drugs, like nucleic acids (5). However, kidney targeting by MNPs has only been shown with polymeric carriers. This research aims to develop a new lipid-based MNP formulation for nucleic acid delivery in kidney disease treatment.